For every purchase made, you are helping further the research of neuroblastoma at NANT.
What is NANT?
Founded in 2000, The New Approaches to Neuroblastoma Therapy (NANT) Consortium is a collaborative group of fourteen children’s cancer centers across North America focused on developing new therapies for children with a type of childhood cancer called neuroblastoma.
Why Focus on Neuroblastoma?
Neuroblastoma is the third most common cancer in children. Half of the children have widespread “high risk” disease at diagnosis, with less than 50% survival. After failing standard therapy, patients have less than 10% survival. When standard therapy fails, NANT offers hope and therapies not available anywhere else to patients and their families. Over 600 children have been treated on NANT trials. NANT has federal, pharmaceutical, and philanthropic grant support. However, it costs approximately $25,000 to treat one child on a clinical trial. Philanthropic support is essential to supporting our mission.